THIRD HARMONIC BIO
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases.
THIRD HARMONIC BIO
Industry:
Biotechnology Life Science
Founded:
2019-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.thirdharmonicbio.com
Total Employee:
11+
Status:
Active
Total Funding:
155 M USD
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Voyager Therapeutics
Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system
Current Advisors List
Current Employees Featured
Investors List
Boxer Capital
Boxer Capital investment in Series B - Third Harmonic Bio
RTW Investments LLC
RTW Investments LLC investment in Series B - Third Harmonic Bio
General Atlantic
General Atlantic investment in Series B - Third Harmonic Bio
BVF Partners
BVF Partners investment in Series B - Third Harmonic Bio
Ajax Health
Ajax Health investment in Series B - Third Harmonic Bio
RA Capital Management
RA Capital Management investment in Series B - Third Harmonic Bio
Commodore Capital
Commodore Capital investment in Series B - Third Harmonic Bio
Deep Track Capital
Deep Track Capital investment in Series B - Third Harmonic Bio
BVF Partners
BVF Partners investment in Series A - Third Harmonic Bio
OrbiMed
OrbiMed investment in Series A - Third Harmonic Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-06 | Third Harmonic Bio Appoints Edward R. Conner, M.D., as Chief Medical Officer |
| 2022-03-09 | Third Harmonic Bio Appoints Robert Ho as Chief Financial Officer |
Official Site Inspections
http://www.thirdharmonicbio.com Semrush global rank: 3.67 M Semrush visits lastest month: 3.84 K
- Host name: 113.243.231.35.bc.googleusercontent.com
- IP address: 35.231.243.113
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Third Harmonic Bio" on Search Engine
Science - Third Harmonic Bio
Science - Third Harmonic Bio. Working. to change the course of inflammatory diseases at the optimal intervention point: targeting mast cells through KIT inhibition. Our current research and development efforts are focused on inflammatory diseases of the skin, airway, and gastrointestinal tract.See details»
Third Harmonic Bio - Crunchbase Company Profile & Funding
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor. Cambridge, Massachusetts, United States. 11-50. Series B. Public. www.thirdharmonicbio.com. 14,508. Highlights. Stock Symbol NASDAQ:THRD. Total Funding Amount. Unlock for free. Contacts 31. Employee Profiles 2. Investors 10.See details»
Third Harmonic Bio Announces Leadership Changes
October 31, 2023. SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor, effective …See details»
Programs - Third Harmonic Bio
Programs - Third Harmonic Bio. A novel. small molecule in the clinic. We’re advancing our lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor.See details»
Third Harmonic, led by former Audentes CEO, launches with …
Published Feb. 16, 2022. Ned Pagliarulo Lead Editor. Permission granted by Third Harmonic. Third Harmonic Bio, a biotech startup founded in 2019 by Atlas Venture, officially launched on Wednesday with $105 million in new funding to advance development of an inflammatory disease drug formerly owned by Novartis.See details»
Third Harmonic Bio Announces First Quarter 2024 Financial
SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal,...See details»
Third Harmonic Bio Announces First Quarter 2024 Financial …
SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal,...See details»
Third Harmonic Bio to Participate in the Jefferies Global
12 hours ago Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the ...See details»
Third Harmonic Bio to Participate in the Jefferies Global …
12 hours ago In this article: SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine ...See details»
Publications - Third Harmonic Bio
Third Harmonic Bio Appoints Robert Ho as Chief Financial Officer 02/16/2022 Third Harmonic Bio Launches to Advance the Next Wave of Medicine for Allergy and InflammationSee details»
Third Harmonic Bio Announces Leadership Changes - Yahoo …
SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases,...See details»
Third Harmonic Bio - Funding, Financials, Valuation & Investors
Their latest funding was raised on Jan 16, 2022 from a Series B round. Third Harmonic Bio is registered under the ticker NASDAQ:THRD . Their stock opened with $17.00 in its Sep 15, 2022 IPO. Third Harmonic Bio is funded by 10 investors. Boxer Capital and RTW Investments are the most recent investors.See details»
Third Harmonic Bio NasdaqGM:THRD Stock Report - Simply Wall St
2 days ago 1Y. 169.6% Updated. 27 May, 2024. Data. Company Financials +. 2 Analysts. Overview. THRD Stock Overview. A biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. About the company. Rewards. Risk Analysis. Makes less than …See details»
Third Harmonic Bio | CipherBio
Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor. Stage: Public. Total Funds Raised: $0.00. Funding Products Partners People News Network. See all funding and science results with CipherBio PRO. Find Prospects. Identify leads, gain more opportunities, close more deals. $1.666 Trillion.See details»
Third Harmonic Bio - Contacts, Employees, Board Members
About. Third Harmonic Bio has 2 current employee profiles, including Chief Financial Officer Robert Ho. Third Harmonic Bio has 7 board members and advisors, including Shao-Lee Lin. Contacts. Chief Scientific Officer. Non-Management , Executive Engineering. 1 email found 1 phone number found. View. COO. Executive Operations. 1 email found. View.See details»
Third Harmonic Bio Announces First Quarter 2024 Financial …
SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced financial results for the first quarter March 31, 2024, recent business …See details»
Third Harmonic Bio, Inc. | AP News - Associated Press News
Third Harmonic Bio, Inc. The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s ...See details»
Third Harmonic Bio Announces Leadership Changes - Third …
SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor, effective November 1, 2023.See details»
2024-05-28 | NDAQ:THRD | Press Release | Third Harmonic Bio Inc
1 day ago About Third Harmonic Bio, Inc. Third Harmonic Bio is a clinical stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases through the development of novel, highly selective, small-molecule inhibitors of KIT, a cell surface receptor that serves as …See details»